Tyra prices $400 million financing to support drug development
Tyra Biosciences ($TYRA) priced an underwritten financing expected to raise approximately $400 million before fees and expenses. The transaction comprises 9,079,000 common shares at $22.03 each and pre-funded warrants covering another 9,078,529 shares at $22.029, with a remaining exercise price of $0.001. All securities are being sold by the company rather than existing shareholders. Proceeds will support its dabogratinib development strategy across upper-tract urothelial cancer, intermediate-ri
0